News

PipelineReview.com2h
Innovent Biologics Showcases “Dual Innovations” at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms
SAN FRANCISCO, CA, USA and SUZHOU, China I June 30, 2025 I Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes ...
PipelineReview.com2h
Mabwell Bioscience and Calico Life Sciences Announce Exclusive Licensing Agreement for Novel IL-11 Targeting Monoclonal Antibody
SHANGHAI, China and SOUTH SAN FRANCISCO, CA, USA I June 26, 2025 I Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH), an innovative biopharmaceutical company, and Calico Life Sciences LLC (Calico) a ...
PipelineReview.com2h
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
AMSTERDAM, The Netherlands I June 30, 2025 I argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, ...
PipelineReview.com2h
ESTEVE to acquire medicine to treat medullary thyroid cancer
BARCELONA, Spain I June 30, 2025 I ESTEVE has entered into an agreement with Sanofi to acquire Caprelsa® (vandetanib) rights in more than 50 countries, a treatment that is used in adults and children ...
PipelineReview.com2d
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
NEW YORK, NY, USA I June 26, 2025 I Pfizer Inc. (NYSE: PFE)today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating ...
PipelineReview.com2d
Cellarity Initiates Phase 1 Clinical Study of CLY-124, a First-in-Class Globin-Switching Oral Medicine for the Treatment of Sickle Cell Disease
Initiation follows successful IND clearance based on preclinical data package indicating robust increase in fetal hemoglobin with no cytotoxicity ...
PipelineReview.com2d
Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA
SEATTLE, WA, USA I June 27, 2025 I Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to ...
PipelineReview.com2d
Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China’s NMPA for Chronic Weight Management
SAN FRANCISCO, CA, USA and SUZHOU, China I June 27, 2025 I Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical ...
PipelineReview.com2d
Metabolics Pharma Announces ENT-03 Generates Sustained Weight Loss and Liver Pathology Improvements in an Animal Model for Obesity
DOYLESTOWN, PA, USA I June 27, 2025 I Metabolics Pharma (“Metabolics”), a privately held, Doylestown-based, clinical-stage biopharmaceutical company ...
PipelineReview.com2d
A2 Bio Announces First Patient Dosed in DENALI-1 Phase 1/2 Clinical Study of A2B395, a Novel Allogeneic Precision CAR T Cell Therapy for Patients with Solid Tumors that Express ...
First-in-human trial uses the A2 Bio proprietary logic-gated Tmod™ technology platform for precision cell therapies providing selective killing of tumor cells while protecting normal cells AGOURA ...
PipelineReview.com2d
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD001
TOKYO, Japan I June 27, 2025 I PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting ...
PipelineReview.com2d
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
ATLANTA, GA, USA I June 27, 2025 I UCB, a global biopharmaceutical company, today announced that the Phase 3 study investigating the safety and efficacy of ...